Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Extends Remsima SC Indications

Subcutaneous Infliximab Gets Nod Covering IBD And Ankylosing Spondylitis

Executive Summary

Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.

You may also be interested in...



Celltrion Opens Up Canadian Market For Remsima SC

Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

Canada Approves Celltrion’s Remsima SC Biosimilar

Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly. 

Celltrion Partners With Intract Pharma For Oral Infliximab

South Korea’s Celltrion has partnered with oral drug delivery specialist Intract Pharma for the formulation of oral infliximab for the treatment of inflammatory bowel disease. Celltrion has also reported year-on-year and quarter-on-quarter growth in sales, along with plans to grow in the US market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel